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DOI 10.1016/j.ccr.2012.01.005SUMMARYThe prostate epithelial lineage hierarchy and the cellular origin for prostate cancer remain inadequately
defined. Using a lineage-tracing approach, we show that adult rodent prostate basal and luminal cells are
independently self-sustained in vivo. Disrupting the tumor suppressor Pten in either lineage led to prostate
cancer initiation. However, the cellular composition and onset dynamics of the resulting tumors are distinc-
tive. Prostate luminal cells are more responsive to Pten null-induced mitogenic signaling. In contrast, basal
cells are resistant to direct transformation. Instead, loss of Pten activity induces the capability of basal cells to
differentiate into transformation-competent luminal cells. Our study suggests that deregulation of epithelial
differentiation is a critical step for the initiation of prostate cancers of basal cell origin.INTRODUCTION cancer remains unclear, partly because the prostate epitheliaDefining the cells of origin for cancer is of great value for accu-
rate tumor prognosis and efficient prevention and therapeutics
(Visvader, 2011). Previously, the identities of the cells of origin
for cancer were assumed based on histological characteriza-
tion of cancers. However, recent transcriptome studies have
revealed that molecular signatures of cancer cells do not
always match their histological appearance (Lim et al., 2009).
Therefore, it can be misleading to determine cells of origin in
the absence of functional lineage-tracing studies (Molyneux
et al., 2010).
Though prostate cancer is the second leading cause of
cancer-related death in males in the United States, it is still
mainly described by qualitative clinical measurements, including
the TNM system and the Gleason grading system (Iczkowski
and Lucia, 2011). The identity of the cellular origin for prostateSignificance
Understanding the cellular origin for cancer can help improve
directly demonstrate that prostate cancer can initiate from both
cells are less susceptible than luminal cells to direct transfor
requires oncogenic-signaling-induced differentiation of adult p
physiological conditions. These studies suggest that deregula
is a critical step for initiation of human prostate cancer with a ba
that induce basal-luminal differentiation may provide an efficie
Cl
lineage hierarchy per se has not been clearly characterized.
Prostate epithelia are composed of three types of epithelial
cells, luminal cells, basal cells, and neuroendocrine cells, of
which the latter are extremely rare (Abate-Shen and Shen,
2000). When prostate epithelial cells are cultured in vitro, a pop-
ulation of transit-amplifying cells is frequently observed (Litvinov
et al., 2006; Peehl, 2005). These transit-amplifying cells express
antigenic markers for both basal and luminal cells. Transit-
amplifying cells are abundant at the developmental stage but
are not detectable in vivo in adults under physiological condi-
tions (Wang et al., 2001).
Using a functional prostate regeneration assay, several inde-
pendent groups, including ours, have demonstrated that some
basal cells in human and murine prostates can generate all
three prostate epithelial cell lineages (Burger et al., 2005;
Goldstein et al., 2010; Lawson et al., 2007; Leong et al.,disease prevention and therapeutics. Our genetic studies
the basal and luminal cell lineages. However, prostate basal
mation. Instead, disease initiation from prostate basal cells
rostate basal cells into luminal cells, which is absent under
tion of the normal-prostate epithelial differentiation program
sal cell origin. Furthermore, suppressing signaling pathways
nt approach to prevent prostate cancer initiation.
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Figure 1. Lineage Tracing Shows that Prostate Basal Cells Only Generate Basal Cells In Vivo
(A) Schematic illustration of the lineage-tracing strategy.
(B–D) Costaining of GFP with K5 and K8 (B), K5 and P63 (C), and synaptophysin (D) in tamoxifen-treated K14-mTmG mice. Arrowheads in (B) and (C) indicate
GFP-labeled basal cells. Arrowhead in (D) points to a neuroendocrine cell.
(E) Timeline for androgen deprivation and replacement experiments.
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Cells of Origin for Prostate Cancer2008; Xin et al., 2005, 2007; Zhang et al., 2011). In addition,
Wang et al. discovered that a rare castration-resistant luminal
prostate cell population also possesses multipotent stem cell
activity (Wang et al., 2009). Of note, the conclusions of those
studies are based on experimental conditions involving cell
transplantation that do not reflect physiological conditions.
Therefore, it remains an open question whether the activities
measured in those assays reflect the obligate or facultative
function of prostate stem cells. Pertaining to this caveat, Liu
et al. recently showed by lineage tracing that prostate luminal
cells are derived from pre-existing luminal cells (Liu et al.,
2011). In addition, a very recent comprehensive lineage-tracing
study on the mammary gland epithelial lineage hierarchy
showed that in the postnatal mammary gland, distinct stem
cells contribute to the maintenance of the myoepithelial and
luminal cell lineages (Van Keymeulen et al., 2011). A similar
comprehensive study on prostate lineage hierarchy is required
to address these controversies.
Previously, prostate luminal cells, transit-amplifying cells, and
basal cells have all been implicated as the cells of origin for pros-
tate cancer (Lawson and Witte, 2007). Two distinct functional
approaches have been used recently to directly investigate the
identity of the cellular origin for prostate cancer. One approach
is to employ genetically engineered mouse models (Ellwood-
Yen et al., 2003; Foster et al., 1997; Iwata et al., 2010; Majumder
et al., 2003; Wang et al., 2003, 2009) to introduce oncogenic
signaling in different prostate cell lineages. Most of these studies
utilized two prostate-specific promoters (Probasin and Nkx3.1).
However, recently it has been shown that these promoters are
active in both luminal cells and some basal cells (Mulholland
et al., 2009; Wu et al., 2007; Zhang et al., 2011). Therefore, one
cannot determine definitively the identities of the cells of origin
for cancer using this approach. Wang et al. recently demon-
strated that some very rare NKX3.1-positive luminal cells in
castrated mice can serve as targets for transformation (Wang
et al., 2009), but it remains undetermined whether other luminal
cells also can serve as the cells of origin for cancer. A pros-
tate-specific antigen-CreERT2 model has recently been demon-
strated to mediate luminal-cell-specific gene expression, but to
date this model has not been extensively utilized (Liu et al.,
2011; Ratnacaram et al., 2008).
The other approach is to genetically modify different prospec-
tively isolated prostate epithelial cell lineages and investigate
their tumorigenic potential by in vivo transplantation assays.
Using this approach, we and others have demonstrated that
murine and human prostate basal cells, but not luminal cells,
can efficiently initiate prostate carcinogenesis in various onco-
genic contexts (Goldstein et al., 2010; Lawson et al., 2010; Xin
et al., 2005). However, a caveat for this approach is that luminal
cells by nature do not proliferate and regenerate prostate tissues
in the in vivo transplantation assay; hence, these studies cannot
exclude that luminal cells also serve as the cells of origin for(F–H) Costaining of GFP with K5 and K8 (F), K5 and P63 (G), and synaptophys
Arrowheads in (F) and (G) indicate GFP-labeled basal cells. Arrowhead in (H) poi
(I) Bar graph shows the percentage of GFP-labeled basal cells in lateral prostate lo
cycles of epithelial regression-regeneration. Data represent the mean ± SD. Also
(J) GFP-labeled basal cells (arrowhead) incorporated BrdU.
See also Figure S1 and Table S1.
Ccancer in vivo. In summary, due to a lack of mouse models
that enable strict lineage targeting in the prostate, it has not
been comprehensively determined previously whether individual
cell lineages can serve as targets for transformation orthotopi-
cally in the prostate. This study aims to reveal how prostate basal
and luminal cell lineages are maintained and the roles of these
two lineages in prostate cancer initiation.
RESULTS
Lineage Tracing Shows that Prostate Basal Cells
Only Generate Basal Cells In Vivo
We employed a lineage-tracing approach to determine in vivo
whether adult murine prostate basal epithelial cells would
generate all three prostate epithelial cell lineages. A K14-CreER
transgenic mouse line was generated previously (Vasioukhin
et al., 1999) in which CreER is driven by the promoter of Keratin
14, a prostate basal cell marker. CreER encodes a Cre recombi-
nase fused to a mutant estrogen ligand-binding domain so that
its activity is induced only in the presence of tamoxifen. To inves-
tigate whether CreER is specifically expressed in prostate basal
cells, K14-CreER transgenic mice were bred with mTmG
reporter mice to generate K14-CreERTg/Tg;mTmGTg/Tg mice
(hereafter referred to as the K14-mTmG mice). The mTmG
mouse line is a double fluorescent reporter line that replaces
the expression of a membrane-targeted Tomato-Red (mT)
protein with a membrane-targeted enhanced green fluores-
cence protein (mG) upon Cre-LoxP-mediated homologous
recombination (Muzumdar et al., 2007) (Figure 1A).
Tamoxifen was injected intraperitoneally (i.p.) into male K14-
mTmG bigenic mice. In contrast to the highly efficient Cre-medi-
ated recombination observed in the skin (Figure S1A available
online), the recombination efficiency in the prostate was lower
and varied among different prostate lobes. On average, 17%
of basal cells in lateral lobes were pulse-labeled with GFP (Table
S1). In contrast, rare and heterogeneously distributed GFP-posi-
tive basal cells were observed in other lobes, and these cells
were hard to quantify. The recombination frequencies among
lobes did not correlate with the K14 promoter activity (Fig-
ure S1B). All GFP-positive cells expressed the basal cell marker
keratin 5 (K5) (Figure 1B, Table S1; n = 2095 cells from five mice).
All of the observed cell nuclei of these GFP-positive cells were
positively stained with another nuclear-localized basal cell
marker, P63 (Figure 1C; n = 1952 cells). In contrast, none of
the examined GFP-positive cells expressed the luminal cell
marker keratin 8 (K8), or the neuroendocrine cell marker synap-
tophysin (Figures 1B and 1D). These data demonstrate that the
CreER expression is restricted to prostate basal cells in the
K14-CreER model.
Adult murine prostate epithelia turn over extremely slowly
under physiological conditions. To determine the fate of prostate
basal cells, we induced extensive epithelial turnover by a classicin (H) in tamoxifen-treated K14-mTmG mice after induced epithelial turnover.
nts to a neuroendocrine cell.
bes of K14-mTmGmice 5 days after tamoxifen induction (6 weeks) and after 2
see Table S1.
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trated in Figure 1E. In this model, prostate tissues atrophy and
regenerate repeatedly in response to fluctuating serum testos-
terone levels. Substantial epithelial cell turnover was induced
after two cycles of prostate regression-regeneration. Immuno-
histochemistry (IHC) analyses showed that all GFP-positive cells
remained basal cells because they expressed K5 but not K8 or
synaptophysin (n = 1295 cells from four mice, Figures 1F and
1H). In addition, the percentage of GFP-labeled basal cells in
lateral prostates did not change after induced epithelial turnover
(Figure 1I; Table S1), suggesting that either all basal cells
possess equal regenerative capacity or the unipotent basal
stem cells and differentiated basal cells are labeled at equal
frequency. The GFP-labeled basal cells have proliferated
because they incorporated BrdU (Figure 1J). Collectively, these
data demonstrate that during prostate regeneration, the GFP-
labeled basal cells proliferated but only gave rise to prostate
basal cells and did not differentiate or undergo lineage conver-
sion to generate other cell lineages.
Prostate Luminal Cell Lineage Is Self-Sustained In Vivo
We generated a K8-CreERT2 mouse model via bacterial artificial
chromosome transgenesis (Zhang et al., 2012), in which CreERT2
is driven by the promoter of the prostate luminal cell marker
keratin 8. The same lineage-tracing approach was employed
using K8-CreERT2Wt/Tg;mTmGWt/Tg (hereafter referred to as
K8-mTmG) mice to determine how prostate luminal epithelial
cells are sustained. GFP was undetectable in vehicle-treated
K8-mTmG mouse prostates (data not shown), but was ex-
pressed abundantly in tamoxifen-treated mouse prostates (Fig-
ure S2A). All GFP-positive cells expressed K8, but not K5 or syn-
aptophysin [n = 31,319 from seven mice (Figures 2A and 2B)],
demonstrating that CreERT2 is only expressed by prostate
luminal epithelial cells in this model. The recombination effi-
ciency varied among different prostate lobes, with that in lateral
lobes the highest (Figures 2E and S2A; Tables S2 and S4). The
recombination frequencies did not correlate with the K8
promoter activity (CreER expression level) among lobes (Fig-
ure S2B). Therefore, the variation in recombination efficiency
may be due to differential local tamoxifen concentrations and
CreER activation status as a result of distinct blood vessel densi-
ties among these different lobes.
To determine how the prostate luminal cell lineage is main-
tained, we aged tamoxifen-treated K8-mTmGmice for 4months.
As shown in Figure 2E and Tables S2–S4, the percentage of
GFP-positive luminal cells in individual lobes did not change after
aging. Since prostate tissues gain weight significantly from
6 weeks to 24 weeks (Figure S2C), it is unlikely that the invariant
percentage of GFP-positive luminal cells after aging is due to
rare cellular turnover. Instead, this result suggests that the
luminal cell lineage may be self-sustained. To further interrogate
this possibility, tamoxifen-treated K8-mTmG mice were sub-
jected to two cycles of prostate regression-regeneration to
induce extensive epithelial turnover, as illustrated in Figure 1E.
IHC analyses showed that the percentages of GFP-positive
luminal cells were not statistically different before and after
induction of epithelial turnover (Figure 2E; Tables S2–S4). In
addition, all GFP-positive cells still expressed K8, but not K5 or
synaptophysin (Figures 2C and 2D), demonstrating that GFP-256 Cancer Cell 21, 253–265, February 14, 2012 ª2012 Elsevier Inc.labeled luminal cells only generate other luminal cells. Overall
these results imply that prostate luminal cells are not replenished
by stem/progenitor cells from other cell lineages during prostate
regeneration.
In addition, the approach illustrated in Figure 2F was em-
ployed to directly investigate the origin of newly formed prostate
luminal cells. Tamoxifen-treated K8-mTmGmice were subjected
to one cycle of prostate regression-regeneration to induce
extensive epithelial turnover. BrdU was administered to label
dividing cells during the period of regeneration. As shown in
Figures 2G and 2H and Tables S2–S4, the GFP+ new luminal
cells (BrdU+K8+) in individual prostate lobes were generated at
a frequency equal to that of the initial pulse-labeling (i.e., the
percentage of GFP+ luminal cells). These data suggest that if
the labeling efficiency of luminal cells is 100%, all new K8+
luminal cells will be GFP+, which means that they would all
come from cells in the luminal lineage existing at the time of
castration and androgen replacement. In summary, these data
directly demonstrate that the luminal cell lineage is self-
sustained.
Prostate Cancer Initiated from Basal-Cell-Specific Loss
of Function of PTEN
To determine the susceptibility of the prostate basal cell lineage
to transformation induced by the loss of function of the tumor
suppressor Pten, we generated K14-CreERTg/Tg;Ptenfl/fl (K14-
Pten) bigenic mice. Tamoxifen was administered to 5-week-old
K14-Pten mice so that Pten was specifically disrupted in pros-
tate basal cells. An ARR2PB-Cre;Ptenfl/fl mouse model for pros-
tate cancer was used as a control, in which Pten is disrupted in
both basal and luminal cells (Wang et al., 2006; Zhang et al.,
2011).
The disease progression status observed in all experimental
mice is summarized in Table 1. Tamoxifen-treated K14-Pten
mice displayed a shaggy fur phenotype (Figure S3A) with
complete penetrance, as reported previously (Backman et al.,
2004; Yao et al., 2006). Disrupting PTEN activity leads to phos-
phorylation of AKT that accumulates at the plasma membrane,
which serves as a reliable marker for PTEN loss. AKT phosphor-
ylation was uniformly detected in the epidermis (Figures S3B and
S3C), demonstrating an efficient Pten knockout in the skin. Aswe
showed previously, the activation of the CreER activity in K14-
Pten mouse prostate basal cells was less efficient (Figure 1),
but Pten was disrupted only in prostate basal cells, as demon-
strated by costaining pAKT with P63 (Figures 3A–3A00). Pten
deletion in prostate basal cells was further confirmed by PCR
genotyping in in vitro cultured prostate spheres derived from
basal cells in tamoxifen-treated K14-Pten mice (Mulholland
et al., 2009) (Figure S3D). Surprisingly, no abnormal epithelial
growth was noted in all the mice examined 1 month post tamox-
ifen treatment (Table 1). However, by 3 months post tamoxifen
treatment, focal hyperplastic growth (Figure 3B) was observed
in 4 out of 11 mice. Those prostatic intraepithelial neoplasia
(PIN) lesions were graded from PIN1 to PIN4 using the nomen-
clature and criteria developed by Park et al. (2002). The PIN
lesions, but not the adjacent normal tissues, expressed pAKT
(Figure 3C). They contained both K5 positive basal cells and
K8 positive luminal cells (Figures 3D and 3E). Luminal cells
expanded in the PIN lesions as measured by the ratio of basal
Figure 2. The Prostate Luminal Cell Lineage Is Self-Sustained In Vivo
(A and B) Costaining of GFP with K5 and K8 (A) and synaptophysin (B) in tamoxifen-treated K8-mTmG mice. Arrowheads and asterisks in (A) denote basal cells
that are not GFP-labeled and GFP-labeled luminal cells, respectively. Arrow in (B) points to a neuroendocrine cell.
(C and D) Costaining of GFPwith K5 and K8 (C) and synaptophysin (D) in tamoxifen-treated K8-mTmGmice after induced epithelial turnover. Arrowheads indicate
that all basal cells are GFP negative. Arrow points to a neuroendocrine cell.
(E) Bar graph shows the percentage of GFP-labeled luminal cells 5 days after tamoxifen induction (6 weeks, black bars), after 4-month aging (red bars), after the
first androgen deprivation (blue bars), and after two cycles of androgen deprivation-replacement experiments (green bars) in anterior (AP), ventral (VP), dorsal
(DP), and lateral (LP) prostate lobes. Data represent the mean ± SD. See Tables S2–S4 for more details.
(F) Timeline for investigating the origin of newly formed luminal cells by BrdU labeling.
(G) Bar graph shows that the frequency of newly formed GFP-positive luminal (GFP+K8+BrdU+/K8+BrdU+) cells reflects that of GFP-labeled luminal (GFP+K8+/
K8+) cells in all four prostate lobes. Data represent the mean ± SD. Also see Tables S2–S4.
(H) A representative image showing BrdU incorporated into luminal cells during prostate regeneration.
See also Figure S2 and Tables S2–S4.
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Table 1. Summary of Disease Progression in K14-Pten and
K8-Pten Mice
Month(s)
Post Tmx
Treatment
Tumor
Incidence
Disease Stage/
Numbers of Mice Mouse ID
K14-PTEN
1 0/5 Normal/5 321,322,323,324,411
3 4/11 Normal/6 293,504,505,509,544
PIN1/1 295
PIN2/1 294
PIN3/1 55
4 Normal/1 92
PIN4/1 91
6 29/31 Normal/2 711,713
PIN2/2 58,59
PIN3/2 52,712
PIN4/4 51,53,56,112
Early cancer/2 57,111
7 PIN3/1 50
PIN4/9 47,48,49,93,94,
95,98,456,460
8 PIN2/1 105
PIN3/2 100,102
PIN4/5 99,103,104,106,865
Early cancer/1 101
K8-PTEN
1 3/3 PIN1/1 89
PIN2/1 69
PIN3/1 146
2 9/9 Early cancer/2 159,924
3 PIN4/3 86,87,773
Early cancer/3 89,772,774
4 Early cancer/1 307
6 15/15 PIN4/1 374
Early cancer/12 226,229,237,375,
451,454,455,498,
499,503,876,898
Adenocarcinoma/2 456,903
Disease stage is defined by the most advanced foci observed in tissues,
most of which are within dorsolateral lobes.
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show clearly that pAKT was also expressed in some basal cells,
further corroborating that Pten deletion has taken place in those
basal cells.
Six to eight months post tamoxifen induction, 29 out of 31
mice developed neoplastic foci at various stages (Table 1).
Figures 4A and 4A0 shows images of K14-Pten mouse prostate
glands 8 months after tamoxifen or vehicle treatment. The pros-
tate lobes appeared less transparent in tamoxifen-treated mice.
H&E staining revealedmultifocal lesions that developed in all four
lobes in this mouse (Figures 4B–4E). A majority of mice devel-
oped focal PIN4 and a few mice developed early prostate
cancer, most frequently in the dorsolateral prostate (DLP). In
most cases, the lumen of a few DLP lobes in individual mice258 Cancer Cell 21, 253–265, February 14, 2012 ª2012 Elsevier Inc.was filled with epithelial cells with nuclear pleomorphism and hy-
perchromasia displaying tufting and cribriform patterns. The
K14-Pten cancers were mainly composed of cells that were
either positive for K5 or K8 (Figures 4F and 4H), with a small
percentage of cells dual positive for K5 and K8. These double-
positive cells express pAKT, suggesting they were also derived
from Pten null basal cells (Figures S4A–S4C). In contrast, there
were many K5+K8+ cells within the ARR2PB-Pten tumors
(Figures 4G and 4H). Most of the K5 positive cells in K14-Pten
mice were also positive for P63 (Figures 4I and 4J). Cells within
the cancerous foci of K14-Pten mice express the androgen
receptor and display secretory function, as demonstrated by
the immunostaining of the secretory proteins of murine dorsolat-
eral lobes (mDLP) (Donjacour et al., 1990) (Figures S4D–S4G).
Finally, very few cells in K14-Pten tumors expressed the neuro-
endocrine cell marker synaptophysin (Figure 4K).
Sporadic basal cells that express pAKTwere observed in glan-
dular structures displaying normal histology (Figure 4L), suggest-
ing that ablating Pten in basal cells is not sufficient to initiate
prostate cancer. In contrast, cancer only initiated upon the emer-
gence of pAKT-expressing luminal cells, thus suggesting that
transition of basal cells into luminal cells may be both essential
and a limiting step for cancer initiation in this model. We found
that disease progression dynamics among experimental mice
varied, with some developing into PIN4 to early cancer; while
others remained as PIN2/3 even 6–8 months post tamoxifen
induction (Figure 4M–4O). This is probably because the transition
from basal cells to luminal cells occurred with different kinetics in
those mice. Overall, our study suggests that loss of function of
PTEN induces differentiation of prostate basal cells into luminal
cells, which is an essential step for disease initiation in thismodel.
To investigate whether K14-Pten tumor cells have functional
repopulating activity, we enzymatically dissociated primary
tumors into single cells, mixed them with embryonic urogenital
sinus mesenchymal cells, and transplanted them subcutane-
ously into immunodeficient host mice for 2 months, as done
previously using the PB-Pten mouse model (Mulholland et al.,
2009). Figure 4Q showed that K14-Pten tumor cells were
capable of regenerating hyperplastic prostate glandular struc-
tures. Those glands were composed of basal cells and luminal
cells that both expressed activated pAKT (Figures 4P–4S),
further confirming that they were Pten null.
Prostate Cancer Derived from Luminal-Cell-Specific
Loss of Function of PTEN
K8-CreERT2Tg/wt;Ptenfl/fl (K8-Pten) mice were generated to
determine whether prostate cancer initiates as a result of
luminal-cell-specific loss of function of Pten (Table 1). K8-Pten
mice developed low-grade PIN lesions in all lobes at full pene-
trance 1 month post tamoxifen treatment (Figures 5A–5A00).
There were fewer pAKT-expressing cells in the anterior prostate
(AP) (data not shown), suggesting that the homologous recombi-
nation is less efficient in the AP.We showed that even when Pten
disruption was induced in very few luminal cells using a lower
dosage of tamoxifen, hyperplastic foci still formed 1 month
post tamoxifen induction (Figures S5A–S5G). This suggests
that the more rapid disease progression in the K8-Pten model,
compared with the K14-Pten model, is due to the intrinsic differ-
ential response of these two cell lineages to Pten ablation, but is
Figure 3. Prostate Cancer Initiated from Basal Cell-Specific Loss of Function of PTEN
(A-A00) Costaining of basal cell marker P63 (A0, A00) with pAKT (A, A00) in K14-Pten mice 1 month post tamoxifen induction. Arrowheads point to pAKT+P63+ cells.
(B) H&E staining of a K14-Pten prostate 3 months post tamoxifen induction reveals the formation of PIN lesions (asterisks).
(C) PIN lesions (asterisks), but not adjacent normal glands, express pAKT.
(D and E) PIN lesions contain both K5-expressing basal cells and K8-expressing luminal cells. Arrowheads indicate K5-expressing basal cells that encapsulate
glands.
(F) Quantification of the expansion of luminal cells in PIN lesions (region B) as compared in normal glands (region A). Data represent the mean ± SD.
(G and H) Pten is disrupted in some basal cells. Arrowheads in (G) and (G0 ) denote a P63-expressing basal cell that expresses pAKT. Arrowhead in (H) points to an
anatomically typical basal cell that expresses pAKT.
See also Figure S3.
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the K8-Ptenmodel. The prostate hyperplasia progressed to PIN4
or early cancers 2–4 months post treatment (Figures 5B–5B00).
Mitotic figures and large atypical cells with enlarged nuclei,
prominent nucleoli, and hyperchromasia were observed. Early
cancer or even frank adenocarcinoma formed unanimously
6 months post tamoxifen induction (Figures 5C–5C00). More
than 95% of the glands in DLP and ventral prostate (VP) dis-
played a tufting and cribriform growth pattern, while the APs
were more histologically heterogeneous, consisting of both
normal and cancerous glands. This is probably due to the rela-
tively lower frequency of homologous recombination in AP, as
mentioned above.
The PIN lesions in ventral prostates were composed predomi-
nantly of K8 positive luminal cells, while K5-or P63-positive basal
cells were almost completely lost (Figure 5D). In comparison, in
the AP and DLP, there was a dramatic expansion of the cells
that were dual positive for K5 and K8 (Figures 5E and 5F), similar
to the double-positive cells observed in the ARR2PB-Ptenmodel
(Figure 4G). The K5 staining in these dual-positive cells was cyto-
plasmic, in sharp contrast to the typical K5 staining in basal cells
that highlights cellular contour. Since these double positive cells
expressed activated AKT, they should have been derived from
K8-positive luminal cells, presumably becoming putative
transit-amplifying cells through dedifferentiation (Figures 5H
and 5I) (Litvinov et al., 2006). They did not express P63 (Figures
5G–5I). In contrast, P63 was only expressed by the K5-positive
basal cells residing at the basement membrane and did not
express activated AKT (Figures 5J–5L), suggesting that theseCP63-expressing cells were bona fide basal cells that did not
undergohomologous recombination. Thedifferential phenotypes
among lobes were observed consistently during the 6 months
post tamoxifen treatment. Cancer cells in all lobes express the
androgen receptor and mDLP, while synaptophysin-expressing
neuroendocrine cells were very rare in all lobes (Figures S5H–
S5N). The same observations were made when both Pten and
P53 were knocked out in luminal cells using K8-CreERT2Tg/Wt;
Ptenfl/fl;P53fl/fl (K8-Pten;P53) mice (data not shown).
Transplantation assays again were performed to determine
whether K8-Pten tumor cells were capable of functional repopu-
lation. H&E staining shows that the outgrowth tissues contained
both normal glandular structures and cancerous lesions (Figures
5M–5O). The normal prostate glandular structures were
composed of a single layer of epithelial cells encircling lumen
filled with eosinophilic secretions. Both prostate basal and
luminal cells were detected in those glands (Figure 5P). They
did not express pAKT (data not shown). We previously showed
that only prostate basal cells are capable of forming such pros-
tate glandular structures upon transplantation (Lawson et al.,
2007; Xin et al., 2005). These results suggest that those normal
glandswere derived fromprostate basal cells and further corrob-
orate that Pten was not disrupted in prostate basal cells in the
K8-Pten model. In contrast, the focal cancerous lesions were
composed of cells that were double-positive for K5 and K8
and expressed pAKT (Figures 5Q and 5R). They did not express
P63 (data not shown). This phenotype recapitulates that of the
original tumors in the AP and DLP, suggesting that those lesions
were derived from Pten-null luminal cells. Collectively, theseancer Cell 21, 253–265, February 14, 2012 ª2012 Elsevier Inc. 259
Figure 4. Progression of Prostate Cancer in the
K14-Pten Model
(A and A0) Representative images of urogenital organs and
dissected prostate lobes from K14-Pten mice 8 months
after induction with vehicle (A0) or tamoxifen (A).
(B–E) Representative images of H&E staining of total
prostate (B), AP (C), DLP (D), and VP (E) lobes of a K14-
Pten mouse 8 months after tamoxifen treatment.
(F–H) Immunostaining of K5 and K8 of a K14-Pten mouse
3 months after tamoxifen treatment (F) and a 4-month old
ARR2PB-Pten mouse (G). (H) Quantification of the
percentage of K5+K8+ andK5+K8 cells in the twomodels.
(I and J) Immunostaining of K5 and P63 in K14-Pten mice
(I) and quantification of the percentage of K5+P63+ and
K5+P63 cells (J).
(K) Synaptophysin-expressing neuroendocrine cells
(arrow) are rare in K14-Pten prostate tumor. Arrowheads
point to P63-expressing basal cells.
(L–L00) Prostate basal cells in normal glands in tamoxifen-
treated K14-Pten mice express pAKT. Arrowheads point
to P63-expressing basal cells that express pAKT.
(M–O) Representative images of H&E staining show that
only mild focal PIN lesions (dot-circled and arrow-pointed
regions) are developed in many K14-Pten mice 6–8
months post tamoxifen treatment.
(P–S) Dissociated prostate cells from K14-Pten tumors are
capable of regenerating abnormal glandular structures. (P)
H&E staining of the outgrown tissues. (Q–S) Immuno-
staining of K5 (Q, arrow) and K8 (Q, arrowhead), P63 (R,
arrowhead), and pAKT (S, arrowhead). Insets in (S) indi-
cate that both basal (arrowhead) and luminal (arrow) cells
express pAKT.
See also Figure S4.
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cells causes prostate cancer.
Castration-Resistant Prostate Cancer Cells Exist in K8-
Pten Prostate Tumors
To investigate the response of K8-Pten tumors to androgen
deprivation, we castrated K8-Pten mice 4 months after tamox-
ifen induction. Seminal vesicles and prostate tumors shrunk
significantly after androgen ablation (Figure 6A and 6A0), which
demonstrated successful androgen ablation and corroborated
that many cancer cells were dependent on androgen for their
survival. Histological analysis confirmed substantial cell death
in the prostate 10 days and 2 months postcastration, as evi-
denced by significant apoptotic bodies inside tumor masses
and cellular debris inside prostate lumen (Figures 6B–6D). IHC
analysis showed that two months postcastration the remaining
VP tumors were composed predominantly of luminal cells (Fig-
ure 6E). The K5 and K8 double-positive cells decreased signifi-
cantly but still persisted in the AP and DLP tumors (Figures 6F
and 6G). These data demonstrate that these luminal cells survive
androgen deprivation and suggest that they may serve as the
cellular origin for castration-resistant prostate cancer.
Prostate Basal Cells Are Resistant to Direct Oncogenic
Transformation
The above studies showed that prostate basal cells were less
sensitive than luminal cells to mitogenic signals mediated by260 Cancer Cell 21, 253–265, February 14, 2012 ª2012 Elsevier Inc.Pten deletion. We wondered whether this was due to the insuffi-
cient oncogenic potency conferred by Pten loss or to the indo-
lent nature of basal cells to transformation. P53-dependent
PTEN-deletion-induced cellular senescence has been shown
to impede the rapid progression of fully developed prostate
adenocarcinoma in the Pten-null prostate cancer model
(Alimonti et al., 2010; Chen et al., 2005). We generated
K14-CreERTg/Tg;Ptenfl/fl;P53fl/fl (K14-Pten;P53) mice and sought
to determine whether prostate basal cells can be directly trans-
formed upon simultaneous deletion of Pten and P53. Two
months post tamoxifen induction, experimental mice developed
severe hyperplastic growth in facial skin, showed signs of
morbidity such as loss of weight and hunched postures, and
had to be euthanized (Figures S6A–S6D). Seminal vesicles and
prostates from tamoxifen-treated K14-Pten;P53 mice were
much smaller compared to the control mice, probably due to
morbidity (Figure S6E). H&E staining showed that prostate
epithelial cells packed tightly due to reduced cytoplasmic
volumes. There were no signs of hyperproliferation (Figures 7A
and 7B; N = 9 mice), which was corroborated by a lack of
Ki67-expressing cells (data not shown). The glandular structures
were mostly composed of K5-positive basal cells that encapsu-
lated K8-positive luminal cells (Figure 7C). Occasionally, basal
cells were reduced in number in some glands (Figure 7D). IHC
analyses showed clearly that pAKT was activated only in P63-
expressing basal cells, demonstrating that Pten was only disrup-
ted in basal cells (Figure 7E). PCR analysis confirmed that
Figure 5. Prostate Cancer Derived from Luminal-
Cell-Specific Disruption of PTEN
(A–C) H&E staining of AP (A0, B0, C0), VP (A, B, C), and DLP
(A00, B00, C00) lobes of K8-Pten mice at 1, 3, and 6 months
post tamoxifen induction. Arrows point to focal hyper-
plasia in AP.
(D–F) Immunostaining of K5 and K8 reveals a distinct
lineage composition among VP (D), AP (E), and DLP (F).
(G–I) P63-expressing basal cells (arrowheads) do not
express pAKT in VP (G), AP (H), and DLP (I).
(J–L) Only K5-expressing basal cells residing at the
basement membrane express P63 (arrowheads) in VP (J),
AP (K), and DLP (L).
(M–R) K8-Pten prostate tumor can repopulate. Repre-
sentative images of H&E staining of outgrown tissues from
dissociated K8-Pten tumor tissues (M–O). Immunostain-
ing of K5 and K8 (P and Q), and pAKT (R) of outgrown
tissues. Arrows indicate cancerous foci.
See also Figure S5.
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Cells of Origin for Prostate Cancersuccessful ablation of P53 (Figure S6F). We were able to keep
four K14-Pten;P53 mice for 3 months after tamoxifen treatment
and observed one PIN4 lesion in one mouse (Figure 7F, arrow),
which demonstrates that cancer can initiate from basal cells
with Pten and P53 deletion. The PIN4 lesion is mainly composed
of luminal cells expressing K8, with some cells expressing K5Cancer Cell 21, 253only or both K5 and K8 (Figure 7G). Some
P63-expressing basal cells expressed pAKT,
suggesting that Pten was disrupted in those
cells (Figure 7H). To exclude that the morbidity
of experimental mice interferes with disease
progression in the prostate, we collected intact
prostate lobes from K14-Pten;P53 mice
2 months post tamoxifen treatment and trans-
planted them under the kidney capsules of
immunodeficient male hosts. Only a few PIN1
lesions were noted in 7-week transplants
(Figures 7I–7K). In contrast, massive lesions at
the PIN4 or early cancer stages were observed
in 15-week transplants (Figures 7L–7N). Within
those cancerous regions, some P63-expressing
basal cells express pAKT while other do not,
suggesting that Pten was disrupted in only
a fraction of basal cells (Figures 7O–7P). Collec-
tively, these results imply that basal cells in situ
are by nature relatively resistant to direct trans-
formation by oncogenic stimuli, which partly
explains why prostate basal cell carcinoma is
so rare (Ali and Epstein, 2007).
DISCUSSION
Obligate versus Facultative Stem Cell
Capacity of the Prostate Basal Cells
Our study demonstrates that adult murine pros-
tate basal and luminal cell lineages are indepen-
dently sustained. We and others also showed
previously, using a transplantation-based pros-
tate regeneration assay, that some prostate
basal cells in both humans and rodents arecapable of generating all three prostate epithelial cell lineages
(Burger et al., 2005; Goldstein et al., 2010; Lawson et al., 2007;
Leong et al., 2008; Xin et al., 2005; Zhang et al., 2011). These
two observations are not mutually contradictory since they
may illustrate the obligate versus facultative activities of stem
cells in the prostate basal cell lineage. In the prostate–265, February 14, 2012 ª2012 Elsevier Inc. 261
Figure 6. Castration-Resistant Prostate Cancer Cells Exist in K8-
Pten Prostate Tumors
(A and A0) Representative images of urogenital organs excluding seminal
vesicles from K8-Pten mice 2 months after a mock surgery (A) and castration
(A0). BL, bladder; UR, Urethra; AP, anterior prostate; VP, ventral prostate; DP,
dorsal prostate; LP, lateral prostate.
(B–G) H&E staining (B–D) and immunostaining of K5 and K8 (E–G) of VP (B and
E), AP (C and F), and DLP (D and G) of K8-Pten mice before castration (B–D),
and 10 days (B0–D0) and 2 months (B00–D00) after castration. Insets in (E)–(G)
show staining of K5 and K8 at bracketed regions in respective images.
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removed from their natural environmental cues, and cocultured
with embryonic urogenital sinus mesenchyme (UGSM) cells
(Xin et al., 2003). It has been shown that embryonic stromal cells
provide inductive signals that are absent in adult murine stromal
cells, which affects epithelial cell differentiation or even changes
their lineage status (Neubauer et al., 1983; Taylor et al., 2006). On
the other hand, stromal-epithelial and epithelial-epithelial inter-
actions in adult mouse prostate may mediate signaling that
prevents basal cells from differentiating into other lineages.
Our observations from the K14-mTmG and K14-Pten models
demonstrate that oncogenic signals like Pten loss can alter the
differentiation program of basal cells. In conclusion, we demon-
strated that at least some prostate basal cells possess unipotent
stem cell activity to maintain this lineage during prostate homeo-
stasis and regeneration. In contrast, the results obtained using
the prostate regeneration assay revealed the plasticity of the
basal cell lineage in response to changes in environmental cues.
Of note, since only up to 21% of prostate basal cells were
labeled with GFP in the K14-mTmG model, we cannot exclude
the possibility that some of unlabeled basal cells can generate262 Cancer Cell 21, 253–265, February 14, 2012 ª2012 Elsevier Inc.luminal cells and neuroendocrine cells. However, our comple-
mentary lineage tracing experiment using the K8-mTmG model
suggests that the luminal cell lineage is mainly self-sustained.
Therefore, even if these additional multipotent basal cells exist,
differentiation of basal cells into luminal cells most likely would
be rare during prostate regeneration. Recently, similar conclu-
sions have been made in the mammary gland (Van Keymeulen
et al., 2011). Though the mammary gland myoepithelial cells
are capable of regenerating the mammary gland in vivo in trans-
plantation assays, genetic lineage-tracing experiments demon-
strated that the myoepithelial and luminal cell lineages are inde-
pendently maintained in adults.
Maintenance of the Luminal Cell Lineage
Previously, a population of castration-resistant NKX3.1-express-
ing (CARN) luminal cells was shown to be able to generate all
three prostate epithelial lineages (Wang et al., 2009). However,
we did not observe in the K8-mTmG mice any descendant of
GFP-positive luminal cells that expressed K5 or synaptophysin,
suggesting that GFP-labeled luminal cells do not differentiate or
convert into the other two epithelial cell lineages, at least in this
mouse model. Since not all prostate luminal cells were labeled
with GFP in the K8-mTmG model, we cannot exclude the possi-
bility that CARN cells were preferentially not labeled under our
experimental conditions.
Several lines of evidence imply the existence of a lineage
hierarchy within the luminal cell lineage. Luminal cells are
heterogeneous with regard to their capacity to retain BrdU
labeling (Tsujimura et al., 2002). The androgen receptor expres-
sion level and activation status are heterogeneous among adult
murine luminal cells (L.X., unpublished data). In addition, some
luminal cells can survive androgen deprivation for an extended
period (Tsujimura et al., 2002). It has been suspected that those
androgen-independent luminal cells represent the committed
progenitor cells in the luminal lineage. Our results showed
that the percentage of GFP-positive luminal cells in castrated
mice was approximately the same as that in intact mice (Fig-
ure 2E), which suggests that differentiated androgen-depen-
dent luminal cells and androgen-independent luminal progen-
itor cells were GFP-labeled at a similar frequency. To date,
the identity of the putative ‘‘luminal progenitor cells’’ remains
undefined.
Alternatively, the androgen-independent survival of prostate
luminal cells may be accounted for by a stochastic model in
which any luminal cells could be conferred with the capacity
for castration resistance when they happen to reside in a specific
niche, such as a specialized anatomical location or a direct
contact with a certain subtype of basal cells. In this scenario,
the luminal cell lineage may be sustained simply by cell duplica-
tion, like the b cells in the pancreas (Dor et al., 2004). Future effort
should be made to distinguish the two models.
Prostate Basal Cells as the Cellular Origin for Prostate
Cancer
Our studies demonstrated that although both prostate basal
and luminal cells can serve as the cellular origin for prostate
cancer, prostate luminal cells are more sensitive to mitogenic
signaling, while basal cells are relatively resistant to transfor-
mation. This is consistent with the fact that luminal cells
Figure 7. Prostate Basal Cells Are Resistant to Direct Oncogenic
Transformation
(A and B) H&E staining of K14-Pten;P53 mouse prostates 2 months after
vehicle (A) or tamoxifen (B) induction. A0 and B0 show images of higher
magnification.
(C and D) Representative images of immunostaining of K5 and K8 of prostates
from K14-Pten;P53 mice 2 months post tamoxifen induction.
(E) Pten is disrupted only in basal cells in K14-Pten;P53mice, as demonstrated
by costaining of pAKT (E and E0 ) and P63 (E and E00). Arrowheads indicate
pAKT-expressing cells that also express P63.
(F–H) H&E (F) and immunostaining of K5/K8 (G) and pAKT/P63 (H) of K14-
Pten;P53 mouse prostates 3 months after tamoxifen induction. Arrow in F
points to a dot-circled PIN4 lesion. Arrowhead in H points to a basal cell
expressing pAKT.
(I–P) Two months after tamoxifen treatment, K14-Pten;P53 prostate glands
were transplanted under renal capsules of immunodeficient male hosts. H&E
staining (I, L, and M) and immunostaining of K5/K8 (J and N) and pAKT/P63
(K, O, and P) of 7-week (I–K) and 15-week (L–P) transplants. Arrowheads in O
and P denote P63-expressing cells that express and do not express pAKT,
respectively.
See also Figure S6.
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Cpossess low levels of H2A.X and hence are more vulnerable to
oncogenic stress (Ja¨a¨maa et al., 2010). The distinctive
responses of these two cell lineages to oncogenic insults
explain why treatment-naive prostate cancers are mostly
composed of luminal cells, while prostate basal cell carcinoma
is very rare.
Intuitively, prostate basal cells would seem to be the preferred
cellular origin for cancer because they are more prone to accu-
mulating genetic alterations than luminal cells. They are less
well differentiated and proliferate more frequently (Bonkhoff
et al., 1994). Additionally, they are proposed to act as a natural
barrier to protect the luminal cell lineage from various insults.
Thus, they are exposed to a more ‘‘hostile’’ environment than
are luminal cells. For example, the basal cells are in closer
contact with various cancer-promoting cytokines generated by
the surrounding reactive stroma as a result of chronic inflamma-
tion (Tuxhorn et al., 2001). However, sincemost prostate cancers
display a luminal cell phenotype, differentiation of basal cells into
luminal cells becomes an essential and probably a rate-limiting
step for cancer initiation and progression, if the cellular origin
for cancer is of the basal cell lineage. This is supported by our
result from the K14-Pten model. Prostate cancer was initiated
in the K14-Pten model with an increased latency. Though Pten
was disrupted specifically only in the prostate basal cells, the
initiation of cancer did not start until the emergence of pAKT-
expressing luminal cells. Since direct differentiation of basal cells
to luminal cells is absent under physiological conditions based
on our lineage-tracing experiments, these results suggest that
deregulation of the normal prostate epithelial differentiation
program is a critical step for initiation of human prostate cancer
with a basal cell origin.
It should be noted that the most ideal way to investigate the
cells of origin for cancer is to perform lineage tracing in the
cancer models. However, we were not able to perform our study
in this way for two reasons. First, activation of CreERT2 by tamox-
ifen is transient. Therefore, homologous recombination may not
be achieved in all the cells that express CreERT2, as we have
shown in the K14-mTmG and K8-mTmG lineage-tracing experi-
ments (Figures 1 and 2). Second, the recombination efficiencies
at different genomic loci are not identical. As shown in Figures
S5O and S5P, GFP expression does not guarantee Pten deletion
in tamoxifen-treated K8-Ptenfl/fl-mTmG triple transgenic mice.
Nevertheless, we found that the specificities of the K14 and K8
promoters are not affected by the genetic background of the
experimental mice (Figures S5Q and S5R). In addition, we
confirmed lineage specific Pten deletion by costaining pAKT
with lineage markers in the K14-Pten and K8-Pten models.
Therefore, we can conclude that neoplasia and tumors in the
K14-Pten and K8-Pten models are derived from basal and
luminal cells, respectively.
A unique feature of prostate cancer is that the disease is
strictly age-dependent. Men under 35 seldom develop prostate
cancer. Our data showed that it takes at least 3 months for K14-
Ptenmouse prostate basal cells to differentiate into luminal cells,
which is almost equivalent to 10 years of human life, suggesting
that this is still an extremely lengthy and inefficient biological
process under certain genetic contexts. This may provide an
additional explanation for the strict age-dependent nature of
human prostate cancer.ancer Cell 21, 253–265, February 14, 2012 ª2012 Elsevier Inc. 263
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and Castration-Resistant Prostate Cancer
Our genetic model also supports that luminal cells can be the
cellular origin for prostate cancer. An intriguing observation
from our K8-Pten model is that the same genetic change causes
tumors with lobe-specific phenotypes with regard to their cellular
composition. The phenotype in VP resembles that of the human
disease because markers of basal cells are absent in prostate
carcinoma,which has servedasadiagnostic criterion for prostate
cancer. In comparison, tumors in the AP and DLP are composed
of cells that express both K5 and K8, and basal cells remain
largely unaffected. A previous study has revealed a compartmen-
talization of gene expression between prostate lobes and identi-
fied dozens of differentially expressed genes between prostate
lobes (Abbott et al., 2003). It is possible that the cellular context,
i.e., the intrinsic differences in gene expression between prostate
lobes, leads to the differential responses of the lobes to the onco-
genic insult. It will be interesting to investigate whether human
prostate luminal cells sharemore similaritywithmurineVP luminal
cells in terms of gene expression profiles. The mechanism by
which basal cells are depleted in the VP is also unknown. We
recently reported that dissociation of basal cells leads to cellular
apoptosis induced by activation of the RhoA/ROCK kinases
(Zhang et al., 2011). One potential mechanism, therefore, could
be that the basal cell layer in ventral prostate is less resilient to
cellular perturbations, so that when prostate glands are enlarged
and distorted due to excessive proliferation of prostate luminal
cells, the cellular contact between ventral prostate basal cells is
attenuated, which alters the signaling that regulates basal cell
survival, such as the RhoA/ROCK-mediated signaling.
Our study also demonstrates that castration-resistant cells in
prostate cancers may originate from luminal cells. This result
excludes the possibility that prostate basal cells are the only
cellular origin for castration-resistant disease. Since there is no
evidence that CARN cells (Wang et al., 2009) were genetically
manipulated by tamoxifen induction in the K8-CreERT2 model
(Figure 2), our study also suggests that CARN cells are not the
only cells of origin for prostate cancer in the luminal cell lineage,
and that castration resistance is not a unique feature of CARN
cells. This observation further highlights the need to identify
the androgen-independent prostate luminal progenitor cells
and to determine the essential signaling that confers the capacity
for androgen-independent survival to luminal cells.
EXPERIMENTAL PROCEDURES
Mouse Procedures
The sources of experimental mice and the genotyping strategies are described
in Supplemental Experimental Procedures. Castration, androgen replace-
ment, dissociation of primary prostate tumors, and tumor cell transplantation
were performed using standard techniques described in Supplemental Exper-
imental Procedures. Tamoxifen (Sigma-Aldrich, St. Louis, MO) was dissolved
into corn oil and was administrated i.p. into experimental mice at the age of
5 weeks once a day for four consecutive days. The dosages used for K14-
CreER and K8-CreERT2 mice were 9 mg/40 g and 2 mg/40 g, respectively.
All animal work were approved by and performed under the regulation of the
Institutional Animal Care Committee of the Baylor College of Medicine.
Histology, Immunohistochemical, and Immunofluorescent Analysis
The procedures for histological and IHC analyses and the information about
primary antibodies were described in Supplemental Experimental Procedures.264 Cancer Cell 21, 253–265, February 14, 2012 ª2012 Elsevier Inc.Paraffin-embedded sections were stained and counterstained with 4,6-diami-
dino-2-phenylindole (DAPI) (Sigma-Aldrich, St. Louis, MO). Secondary anti-
bodies were labeled with Alexa Fluro 488, 594, 633 (Invitrogen, Carlsbad,
CA). Immunofluorescence staining was imaged using an Olympus BX60 fluo-
rescence microscope or a Leica EL6000 confocal microscope. Cell counting
was performed either manually or via ImagePro Software.
Statistics
All experiments were performed using 4–10 mice in independent experiments.
Data are presented as mean ± SD. Student’s t test was used to determine
significance between groups. For all statistical tests, the 0.05 level of confi-
dence was accepted for statistical significance.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, four tables, and Supplemental
Experimental Procedures and can be found with this article online at doi:10.
1016/j.ccr.2012.01.005.
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